Stoke Therapeutics

Company snapshot

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, z

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Stoke Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Stoke Therapeutics.

1. Jun 8, 2026 Clinical update

   Transanal irrigation with Peristeen Anal Irrigation — Approved

2. Jun 5, 2026 Clinical update

   STK-002 — Phase 1

3. Jun 5, 2026 Clinical update

   STK-001 - Single Ascending Doses — Phase 2

4. May 26, 2026 Clinical update

   STK-001, STK-001 — Phase 3

5. May 23, 2026 Clinical update

   zorevunersen — Phase 3

View all clinical trial activity →

• What is Stoke Therapeutics?

  Stoke Therapeutics is a pharma organization headquartered in Bedford, USA. It trades on NYSE under ticker STOK. Primary therapeutic focus areas include Dravet Syndrome, Dravet syndrome, Autosomal Dominant Optic Atrophy, Valvular Stenosis, Pain Relief in Labour. NovaPharmaNews lin

• Is Stoke Therapeutics publicly traded?

  Yes. Stoke Therapeutics is listed with ticker STOK on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Stoke Therapeutics develop or market?

  We link 4 drug profile(s) where Stoke Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/stoke-therapeutics#company-drugs.

• What are the latest developments for Stoke Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Stoke Therapeutics focus on?

  Stoke Therapeutics focuses on Dravet Syndrome, Dravet syndrome, Autosomal Dominant Optic Atrophy based on our analysis of their pipeline programs and drug development activities.